Olumiant (baricitinib) vs Ilaris (canakinumab)

Olumiant (baricitinib) is an oral Janus kinase (JAK) inhibitor that is approved for the treatment of moderate to severe rheumatoid arthritis and has been used off-label for conditions like COVID-19. It works by interfering with the pathway that leads to inflammation and immune response. In contrast, Ilaris (canakinumab) is a biologic injectable medication that blocks interleukin-1 beta, a component of the immune system that can cause inflammation, and is used to treat rare autoinflammatory conditions like Cryopyrin-Associated Periodic Syndromes (CAPS) and systemic juvenile idiopathic arthritis. When deciding between Olumiant and Ilaris, it's crucial to consider the specific condition being treated, as Olumiant is generally used for rheumatoid arthritis, while Ilaris targets specific autoinflammatory syndromes. Additionally, the route of administration (oral for Olumiant, injectable for Ilaris) and the mechanism of action differ significantly, which may influence a patient's choice based on convenience, tolerability, and underlying health conditions. It is essential to consult with a healthcare provider to determine which medication is appropriate for an individual's specific medical needs and circumstances.

Difference between Olumiant and Ilaris

Metric	Olumiant (baricitinib)	Ilaris (canakinumab)
Generic name	Baricitinib	Canakinumab
Indications	Rheumatoid arthritis, COVID-19 (under Emergency Use Authorization)	Cryopyrin-Associated Periodic Syndromes, Systemic Juvenile Idiopathic Arthritis, Familial Mediterranean Fever, and other conditions
Mechanism of action	Janus kinase (JAK) inhibitor, which modulates the immune system	Monoclonal antibody that inhibits interleukin-1 beta
Brand names	Olumiant	Ilaris
Administrative route	Oral	Subcutaneous injection
Side effects	Upper respiratory tract infections, nausea, headache, hypertension	Infections, vertigo, injection site reactions, weight gain
Contraindications	Active tuberculosis, serious infections, severe hepatic impairment	Active infections, hypersensitivity to canakinumab or excipients
Drug class	JAK inhibitor	Interleukin-1 beta blocker
Manufacturer	Eli Lilly and Company	Novartis Pharmaceuticals

Efficacy

Introduction to Olumiant (Baricitinib) in Rheumatoid Arthritis

Olumiant (baricitinib) is an oral medication approved for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. As a Janus kinase (JAK) inhibitor, baricitinib interferes with the JAK-STAT signaling pathway, which is known to play a pivotal role in the inflammatory process of RA. Clinical trials have demonstrated the efficacy of baricitinib in reducing the signs and symptoms of RA, improving physical function, and inhibiting the progression of structural damage as assessed by X-ray.

Efficacy of Olumiant (Baricitinib) in Clinical Trials

The efficacy of Olumiant (baricitinib) has been established through several pivotal phase III clinical trials, including the RA-BEACON and RA-BUILD studies. These trials showed that baricitinib was superior to placebo in achieving American College of Rheumatology 20 (ACR20) response, which indicates a 20% improvement in RA symptoms. Moreover, patients treated with baricitinib also experienced improvements in ACR50 and ACR70 responses, representing 50% and 70% improvements respectively. Additionally, baricitinib has been shown to reduce Disease Activity Score in 28 joints (DAS28-ESR) and enhance the Health Assessment Questionnaire Disability Index (HAQ-DI) scores, reflecting better disease control and quality of life.

Introduction to Ilaris (Canakinumab) in Rheumatoid Arthritis

Ilaris (canakinumab) is a human monoclonal antibody targeting interleukin-1 beta (IL-1β), a cytokine that plays a key role in the inflammatory response in RA. While Ilaris is primarily approved for the treatment of several rare auto-inflammatory syndromes, its use in rheumatoid arthritis is considered off-label. Preliminary data from small studies and case reports suggest that canakinumab may offer therapeutic benefits in reducing inflammation and pain in patients with RA, particularly in those who have not responded adequately to conventional treatments.

Efficacy of Ilaris (Canakinumab) in Rheumatoid Arthritis

Despite the potential observed in small-scale studies, the efficacy of Ilaris (canakinumab) in the treatment of rheumatoid arthritis has not been established in large-scale, randomized clinical trials. Therefore, its use in RA remains off-label, and further research is necessary to fully understand its benefits and risks in this patient population. Clinicians considering canakinumab for RA should weigh the current evidence and make individualized treatment decisions based on the patient's overall clinical picture and response to existing therapies.

Regulatory Agency Approvals

Olumiant

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Ilaris

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Olumiant or Ilaris today

If Olumiant or Ilaris are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Olumiant

Buy Ilaris

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: